{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:02:14Z","timestamp":1791666134695,"version":"4.3.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":66,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-026-05051-4","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T19:45:03Z","timestamp":1780429503000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Obinutuzumab is effective for refractory primary membranous nephropathy"],"prefix":"10.1186","volume":"27","author":[{"given":"Na","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baobao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zunsong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"issue":"10","key":"5051_CR1","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1681\/ASN.2015080953","volume":"27","author":"HZ Qin","year":"2016","unstructured":"Qin HZ, et al. Combined Assessment of Phospholipase A2 Receptor Autoantibodies and Glomerular Deposits in Membranous Nephropathy. J Am Soc Nephrol. 2016;27(10):3195\u2013203.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"5051_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","volume":"361","author":"LH Beck Jr","year":"2009","unstructured":"Beck LH Jr., et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11\u201321.","journal-title":"N Engl J Med"},{"issue":"11","key":"5051_CR3","first-page":"1074","volume":"372","author":"C Meyer-Schwesinger","year":"2015","unstructured":"Meyer-Schwesinger C, Lambeau G, Stahl RA. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med. 2015;372(11):1074\u20135.","journal-title":"N Engl J Med"},{"issue":"4","key":"5051_CR4","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","volume":"100","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, et al. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4):753\u201379.","journal-title":"Kidney Int"},{"issue":"1","key":"5051_CR5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa1814427","volume":"381","author":"FC Fervenza","year":"2019","unstructured":"Fervenza FC, et al. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. N Engl J Med. 2019;381(1):36\u201346.","journal-title":"N Engl J Med"},{"issue":"3","key":"5051_CR6","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1365-2141.2010.08428.x","volume":"152","author":"M Patz","year":"2011","unstructured":"Patz M, et al. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. Br J Haematol. 2011;152(3):295\u2013306.","journal-title":"Br J Haematol"},{"issue":"22","key":"5051_CR7","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","volume":"115","author":"E M\u00f6ssner","year":"2010","unstructured":"M\u00f6ssner E, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115(22):4393\u2013402.","journal-title":"Blood"},{"issue":"14","key":"5051_CR8","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","volume":"377","author":"R Marcus","year":"2017","unstructured":"Marcus R, et al. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. N Engl J Med. 2017;377(14):1331\u201344.","journal-title":"N Engl J Med"},{"issue":"12","key":"5051_CR9","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","volume":"370","author":"V Goede","year":"2014","unstructured":"Goede V, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101\u201310.","journal-title":"N Engl J Med"},{"issue":"9","key":"5051_CR10","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1093\/rheumatology\/keab916","volume":"61","author":"NA Amudala","year":"2022","unstructured":"Amudala NA, et al. Obinutuzumab as treatment for ANCA-associated vasculitis. Rheumatology (Oxford). 2022;61(9):3814\u20137.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"5051_CR11","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","volume":"81","author":"RA Furie","year":"2022","unstructured":"Furie RA, et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2022;81(1):100\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"5051_CR12","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.ekir.2020.06.030","volume":"5","author":"S Sethi","year":"2020","unstructured":"Sethi S, et al. Obinutuzumab is Effective for the Treatment of Refractory Membranous Nephropathy. Kidney Int Rep. 2020;5(9):1515\u20138.","journal-title":"Kidney Int Rep"},{"issue":"6","key":"5051_CR13","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1053\/j.ajkd.2020.02.444","volume":"76","author":"N Klomjit","year":"2020","unstructured":"Klomjit N, Fervenza FC, Zand L. Successful Treatment of Patients With Refractory PLA(2)R-Associated Membranous Nephropathy With Obinutuzumab: A Report of 3 Cases. Am J Kidney Dis. 2020;76(6):883\u20138.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"5051_CR14","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1093\/ndt\/gfae230","volume":"40","author":"M Xu","year":"2025","unstructured":"Xu M, et al. Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy. Nephrol Dial Transpl. 2025;40(5):978\u201386.","journal-title":"Nephrol Dial Transpl"},{"issue":"12","key":"5051_CR15","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.2215\/CJN.0000000000000555","volume":"19","author":"X Hu","year":"2024","unstructured":"Hu X, et al. Comparison of Obinutuzumab and Rituximab for Treating Primary Membranous Nephropathy. Clin J Am Soc Nephrol. 2024;19(12):1594\u2013602.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"5051_CR16","first-page":"979","volume":"16","author":"J Di","year":"2018","unstructured":"Di J, et al. Efficacy and safety of long-course tacrolimus treatment for idiopathic membranous nephropathy. Exp Ther Med. 2018;16(2):979\u201384.","journal-title":"Exp Ther Med"},{"issue":"1","key":"5051_CR17","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1080\/0886022X.2019.1637758","volume":"41","author":"H Zou","year":"2019","unstructured":"Zou H, Jiang F, Xu G. Effectiveness and safety of cyclophosphamide or tacrolimus therapy for idiopathic membranous nephropathy. Ren Fail. 2019;41(1):673\u201381.","journal-title":"Ren Fail"},{"issue":"1","key":"5051_CR18","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12882-022-02761-3","volume":"23","author":"R Hudson","year":"2022","unstructured":"Hudson R, et al. Treatment resistant M-type phospholipase A2 receptor associated membranous nephropathy responds to obinutuzumab: a report of two cases. BMC Nephrol. 2022;23(1):134.","journal-title":"BMC Nephrol"},{"issue":"8","key":"5051_CR19","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1681\/ASN.2010111125","volume":"22","author":"LH Beck Jr","year":"2011","unstructured":"Beck LH Jr., et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol. 2011;22(8):1543\u201350.","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"5051_CR20","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1002\/art.30466","volume":"63","author":"EM Vital","year":"2011","unstructured":"Vital EM, et al. B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum. 2011;63(10):3038\u201347.","journal-title":"Arthritis Rheum"},{"key":"5051_CR21","doi-asserted-by":"publisher","first-page":"738788","DOI":"10.3389\/fimmu.2021.738788","volume":"12","author":"M Teisseyre","year":"2021","unstructured":"Teisseyre M, et al. Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy. Front Immunol. 2021;12:738788.","journal-title":"Front Immunol"},{"issue":"4","key":"5051_CR22","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.ekir.2021.01.022","volume":"6","author":"M Teisseyre","year":"2021","unstructured":"Teisseyre M, et al. Analysis and Management of Rituximab Resistance in PLA2R1-Associated Membranous Nephropathy. Kidney Int Rep. 2021;6(4):1183\u20138.","journal-title":"Kidney Int Rep"},{"issue":"8","key":"5051_CR23","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1002\/art.39167","volume":"67","author":"V Reddy","year":"2015","unstructured":"Reddy V, et al. Internalization of rituximab and the efficiency of B Cell depletion in rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheumatol. 2015;67(8):2046\u201355.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"5051_CR24","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.ekir.2024.12.012","volume":"10","author":"M Teisseyre","year":"2025","unstructured":"Teisseyre M, et al. Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies. Kidney Int Rep. 2025;10(3):753\u201361.","journal-title":"Kidney Int Rep"},{"issue":"4","key":"5051_CR25","doi-asserted-by":"publisher","first-page":"529","DOI":"10.4049\/jimmunol.2300647","volume":"212","author":"T Rispens","year":"2024","unstructured":"Rispens T, et al. Cross-Reactivity of Antibodies to Rituximab with Other Therapeutic Anti-CD20 Antibodies. J Immunol. 2024;212(4):529\u201333.","journal-title":"J Immunol"},{"issue":"8","key":"5051_CR26","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1016\/j.ekir.2025.04.059","volume":"10","author":"M Allinovi","year":"2025","unstructured":"Allinovi M, et al. Anti-Rituximab Antibodies Occurrence and Clinical Outcomes in Patients With Primary Membranous Nephropathy. Kidney Int Rep. 2025;10(8):2621\u20139.","journal-title":"Kidney Int Rep"},{"issue":"8","key":"5051_CR27","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1016\/j.ekir.2024.05.004","volume":"9","author":"X Su","year":"2024","unstructured":"Su X, et al. Obinutuzumab as Initial or Second-Line Therapy in Patients With Primary Membranous Nephropathy. Kidney Int Rep. 2024;9(8):2386\u201398.","journal-title":"Kidney Int Rep"},{"issue":"7","key":"5051_CR28","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1093\/rheumatology\/kex067","volume":"56","author":"V Reddy","year":"2017","unstructured":"Reddy V, et al. Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples. Rheumatology (Oxford). 2017;56(7):1227\u201337.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"5051_CR29","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/art.41608","volume":"73","author":"AD Marinov","year":"2021","unstructured":"Marinov AD, et al. The Type II Anti-CD20 Antibody Obinutuzumab (GA101) Is More Effective Than Rituximab at Depleting B Cells and Treating Disease in a Murine Lupus Model. Arthritis Rheumatol. 2021;73(5):826\u201336.","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"5051_CR30","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/bjh.13764","volume":"171","author":"A Awasthi","year":"2015","unstructured":"Awasthi A, et al. Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive\/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALL. Br J Haematol. 2015;171(5):763\u201375.","journal-title":"Br J Haematol"},{"issue":"10","key":"5051_CR31","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.2215\/CJN.01460217","volume":"12","author":"J Wang","year":"2017","unstructured":"Wang J, et al. Circulating Antibodies against Thrombospondin Type-I Domain-Containing 7A in Chinese Patients with Idiopathic Membranous Nephropathy. Clin J Am Soc Nephrol. 2017;12(10):1642\u201351.","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-05051-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05051-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-05051-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T01:09:16Z","timestamp":1786064956000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-05051-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5051"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-05051-4","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"5 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study protocol was reviewed and approved by the Ethics Committee of the First Affiliated Hospital of Shandong First Medical University, approval number #S347, which was conducted in accordance with the Declaration of Helsinki. All participants were provided with written and oral explanations prior to participation. Informed consent to participate was obtained from all of the participants in the study.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"458"}}